Representative review articles

Depping R, Jelkmann W, Kosyna FK
Nuclear-cytoplasmatic shuttling of proteins in control of cellular oxygen sensing

J Mol Med (Berl) 93: 599-608, 2015

 

Schraivogel D, Schindler SG, Danner J, Kremmer E, Pfaff J, Hannus S, Depping R, Meister G

Importin-beta facilitates nuclear import of human GW proteins and balances cytoplasmic gene silencing protein levels

Nucleic Acids Res. 2015 Jul 13. pii: gkv705. [Epub ahead of print], 2015

 

Kosyna FK, Nagel M, Kluxen L, Kraushaar K, Depping R

The importin α/β-specific inhibitor Ivermectin affects HIF-dependent hypoxia response pathways

Biol Chem pii: /j/bchm.ahead-of-print/hsz-2015-0171/hsz-2015-0171.xml [Epub ahead of print]

 

Gemoll T, Epping F, Heinrich L, Fritzsche B, Roblick UJ, Szymczak S, Hartwig S, Depping R, Bruch, HP, Thorns C, Lehr S, Paech A, Habermann JK

Increased cathepsin D protein expression is a biomarker for osteosarcomas, pulmonary metastases and other bone malignancies

Oncotarget 6(18): 16517-26, 2015

 

Jelkmann W

The ESA scenario gets complex: from biosimilar epoetins to activin traps

Nephrol Dial Transplant 30(4): 553-9, 2015

 

Elliott S, Sinclair A, Collins H, Rice L, Jelkmann W

Progress in detecting cell-surface protein receptors: the erythropoietin receptor example

Ann Hematol 93: 181-192, 2014

 

 

Jelkmann W

Xenon Misuse in Sports-Increase of Hypoxia-Inducible Factors and Erythropoietin, or Nothing but "Hot Air"?

Dtsch Z Sportmed 65:267-271, 2014

 

Jelkmann I, Jelkmann W
Impact of erythropoietin on intensive care unit patients
Transfus Med Hemother 40:310-318, 2013

Jelkmann W, Elliott S
Erythropoietin and the vascular wall: The controversy continues
Nutr Metab Cardiovasc 23:37-43, 2013

 

Aapro M, Jelkmann W, Constantinescu SN, Leyland-Jones B:
Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer
Br J Cancer 107(7): 1249-58, 2012


Jelkmann W:
Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments
Expert Opin Biol Ther 12(5): 581-92, 2012

Jelkmann W, Lundby C:
Blood doping and its detection.
Blood 118: 2395-2404, 2011

Jelkmann W:
Regulation of erythropoietin production.
J Physiol 589: 1251-1258, 2011

Jelkmann W:
Biosimilar epoetins and other "follow-on" biologics: Update on the European experiences.
Am J Hematol 85: 771-780, 2010

Jelkmann W:
Erythropoiesis stimulating agents and techniques: A challenge for doping analysts.
Curr Med Chem 16: 1236-47, 2009

Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ:
The erythropoietin receptor in normal and cancer tissues.
Crit Rev Oncol Hematol 67: 39-61, 2008

Bruegge K, Jelkmann W, Metzen E:
Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-a hydroxylases.
Curr Med Chem 14: 1853-1862, 2007

Jelkmann W:
Erythropoietin after a century of research: younger than ever.
Eur J Haematol. 78: 183-205, 2007

Hellwig-Bürgel T, Stiehl DP, Wagner AE, Metzen E, Jelkmann W.Review:
Hypoxia-inducible factor-1 (HIF-1): a novel transcription factor in immune reactions.
J Interfer Cytokine Res 25: 297-310, 2005

Jelkmann W:
Effects of erythropoietin on brain function.
Curr Pharm Biotechnol 6, 65-79, 2005

Jelkmann W:
Molecular biology of erythropoietin.
Intern Med 43, 649-659, 2004

Klinger MHF, Jelkmann W:
Role of blood platelets in infection and inflammation.
J Interfer Cytokine Res 22: 913-922, 2002

Wolber E-M, Jelkmann W:
Thrombopoietin: The novel hepatic hormone.
News Physiol Sci 17: 6-10, 2002

Jelkmann W:
Pitfalls in the measurement of circulating vascular endothelial growth factor.
Clin Chem 47:617-623, 2001